此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Secondary Prevention of Dug-related Problems Through Digital Health

Secondary Prevention of Dug-related Problems Through Patient Empowerment Through Digital Health

The purpose of this study is to evaluate the clinical impact of a program for the secondary prevention of drug-realted problems (DRP) focused on the patient empowerment through Digital Health in patients who visit the Emergency Department (ED) of the Hospital de la Santa Creu i Sant Pau (HSCiSP) for a health problem related to medication in terms of readmissions, revisits and quality of life.

研究概览

详细说明

After being infomed about the estudy and potential risks, all patients who meet the eligibility requirements and giving written informed consent, will be randomized.

The project is structured in two consecutive phases.

  1. st Phase: 3-month randomized pilot study. Patients will be randomized with a 1:1 distribution to be included in the Drug Code Active Patient or DCAP (intervention group) or to receive usual care (control group). The pilot study will confirm whether the proposed methodology is feasible to implement it on a large scale, as well as providing the information necessary to calculate the sample of patients according to the main objective of the study.
  2. nd Phase: Randomized clinical trial lasting 18 months (6 of which will be recruitment and 12 months follow-up) following the methodology described for the pilot in a larger sample of patients until the calculated sample size is achieved.

研究类型

介入性

注册 (预期的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Ana Juanes Borrego, Doctor
  • 电话号码:7459 932 91 90 00
  • 邮箱:ajuanes@santpau.cat

研究联系人备份

  • 姓名:Jesús Ruiz Ramos, Doctor
  • 电话号码:7459 932 91 90 00
  • 邮箱:jruiz@santpau.cat

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age greater than or equal to 18 years.
  • Visit ED for a DRP caused bu a drug of the ATC groups A, B, C or N.
  • Be independent for activities of daily living (equivalent to Barthel 100).
  • Have a Chalson Comorbidity Index 2 <= 3.
  • Not present cognitive impairment.
  • Be directly responsible for pharmacotherapy.
  • Have a mobile device compatible with the MyPlan mobile application and access to Wi-Fi or mobile data, enabling the use of the technology platform from home.

Exclusion Criteria:

  • Important language barrier.
  • Impossibility of carrying out the necessary questionnaires or interviews defined in the methods of this study.
  • Mental pathology that makes the autonomous use of technology impossible or that represents a safety problem for the patient according to clinical criteria.
  • Patients not residing in the territory who cannot be followed-up later.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Drug Code Active Patient o DCAP

Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.

Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge.

Inclusion in the active group involves the use of MyPlan digital health tool that aims to improve clinical-patient communication, enahnce patient empowerment, improve early detection of side effects and allows professionals to individualize interventions.
安慰剂比较:Standard care

Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.

Patients will receive follow-up by videoconference 48 hours after discharge and in the phase II, at 6 and 12 months after discharge.

Inclusion in the control group do not involves the use of MyPlan digital health tool. Patients will receive the standard of care.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Clinical impact of a digitial health tool for secondary prevention of DRP focused on patient empowerment.
大体时间:Baseline, 48h after discharge, 30-day and 90-day after discharge (in phase I, Pilot Trial)
Change in clinical impact during the follow-up time will be evaluated in terms of number of readmissions, number of revisits and quality of life (based on the result obtained in the EQ-5D-3L51 questionnaire)
Baseline, 48h after discharge, 30-day and 90-day after discharge (in phase I, Pilot Trial)
Clinical impact of a digitial health tool for secondary prevention of DRP focused on patient empowerment.
大体时间:Baseline, 48h after discharge, 6-month and 12-month after discharge (in phase II, Clinical Trial)
Change in clinical impact during the follow-up time will be evaluated in terms of number of readmissions, number of revisits and quality of life (based on the result obtained in the EQ-5D-3L51 questionnaire)
Baseline, 48h after discharge, 6-month and 12-month after discharge (in phase II, Clinical Trial)

次要结果测量

结果测量
措施说明
大体时间
Identify, classify, and quantify DRP that cause urgent care in a tertiary hospital in this patient population.
大体时间:Baseline
Type of DRP that promotes ED visits characterized according to the three dimensions of the Third Consensus of Granada (Need, Effectiveness and Safety)
Baseline
Identify risk factors for ED visits related to DRP
大体时间:Baseline
Age, sex, social and familiar environment, blood presure (mmHg), heart frequency (bpm), Hb1Ac (%), pain (visual analog scale), weight (kg) and height (cm), chronic kidney disease, number of drugs at admission and at discharge, number of chronic health problems.
Baseline
Identify which groups of drugs are more frequently associated to DRP
大体时间:Baseline
Using ATC group classification
Baseline
Change in the patient therapeutic adherence
大体时间:Baseline, 48h after discharge, 30-day and 90-day after discharge (in phase I, Pilot Trial)
Active days on the MyPlan platform, functionalities used, number of queries made through platform messaging
Baseline, 48h after discharge, 30-day and 90-day after discharge (in phase I, Pilot Trial)
Change in the patient therapeutic adherence
大体时间:Baseline, 48h after discharge, 6-month and 12-month after discharge (in phase II, Clinical Trial)
Active days on the MyPlan platform, functionalities used, number of queries made through platform messaging
Baseline, 48h after discharge, 6-month and 12-month after discharge (in phase II, Clinical Trial)
Mesure therapeutic complexity
大体时间:Baseline
Using patient Medication Regimen Complexity Index (pMRCI-S) questionnaire
Baseline
Identify predictive factors of a greater capacity for digital empowerment.
大体时间:Baseline
Using the CAMBADOS questionnaire
Baseline
Measure the usability and satisfaction of patients, caregivers and professionals of the MyPlan digital health tool
大体时间:90-day after discharge (in phase I, Pilot Trial)
Using the TrilemaSalud questionnaire
90-day after discharge (in phase I, Pilot Trial)
Measure the usability and satisfaction of patients, caregivers and professionals of the MyPlan digital health tool
大体时间:12-month after discharge (in phase II, Clinical Trial)
Using the TrilemaSalud questionnaire
12-month after discharge (in phase II, Clinical Trial)
Change in the quality of life of patients in the active group
大体时间:Baseline, 30-day and 90-day after discharge (in phase I, Pilot Trial)
Using the EQ-5D-3L51 questionnaire
Baseline, 30-day and 90-day after discharge (in phase I, Pilot Trial)
Change in the quality of life of patients in the active group
大体时间:Baseline, 6-month and 12-month after discharge (in phase II, Clinical Trial)
Using the EQ-5D-3L51 questionnaire
Baseline, 6-month and 12-month after discharge (in phase II, Clinical Trial)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Laia López Vinardell、Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年4月1日

初级完成 (预期的)

2021年10月1日

研究完成 (预期的)

2023年4月1日

研究注册日期

首次提交

2021年3月18日

首先提交符合 QC 标准的

2021年4月8日

首次发布 (实际的)

2021年4月12日

研究记录更新

最后更新发布 (实际的)

2021年4月12日

上次提交的符合 QC 标准的更新

2021年4月8日

最后验证

2021年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • IIBSP-COD-2019-46

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Monitor clinical trial will have access to all study data

IPD 共享时间框架

Data will be avaliable for monitor during the whole study period

IPD 共享访问标准

All data may be analysed and revised during the whole study period by the monitor and investigators

IPD 共享支持信息类型

  • 研究协议
  • 统计分析计划 (SAP)
  • 知情同意书 (ICF)
  • 临床研究报告(CSR)
  • 解析代码

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅